Editorial comment

Adenocarcinoma of the prostate is a major health concern in the United States, with 31,620 deaths estimated for 2019.1 A recent population-based study of nearly 400,000 patients found that radical prostatectomy (RP) was the most commonly utilized treatment in the United States for intermediate- and high-risk patients.2 In men under aged 70 in these risk groups, RP accounted for 48%-82% of first line therapy.2 These patients with intermediate- and high-risk disease represent the population most to be at high risk for recurrence following RP, historically defined by the presence of extracapsular extension, seminal vesicle involvement, or positive surgical margins.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research